pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin

García, Mónica Cristina; Calderón-Montaño, José Manuel; Rueda, M.; Longhi, Marcela Raquel; Rabasco, A. M.; López‐Lázaro, Miguel; Prieto-Dapena, Francisco; González-Rodrı́guez, Marı́a Luisa

doi:10.1016/j.ijpharm.2022.121691

Cited by 18 publications

(4 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The acidic pH of the tumor microenvironment was also considered as a targeting issue for nanomedicine-based drug targeting because nano-dimensional carriers can be designed to be sensitive to acidic pH and then to accelerate the liberation of anticancer drugs in tumor tissue rather than blood neutral/basic pH [ 52 , 53 ]. Hwang et al reported that pH-sensitive nanoparticles improve intracellular delivery of anticancer drugs and efficiently inhibit the viability of cancer cells at an acidic pH [ 52 ].…”

Section: Discussionmentioning

confidence: 99%

“…Hwang et al reported that pH-sensitive nanoparticles improve intracellular delivery of anticancer drugs and efficiently inhibit the viability of cancer cells at an acidic pH [ 52 ]. Garcia et al also reported that the acidic pH of tumor accelerates DOX release from pH-sensitive liposomes and then efficiently kills breast cancer cells [ 53 ]. Our results also show that the DOX release rate from ChitoHISss nanoparticles was accelerated at an acidic pH, such as pH 6.0 and 6.8 ( Figure 5 b).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

pH and Redox-Dual Sensitive Chitosan Nanoparticles Having Methyl Ester and Disulfide Linkages for Drug Targeting against Cholangiocarcinoma Cells

et al. 2022

View full text Add to dashboard Cite

The aim of this study is to prepare pH- and redox-sensitive nanoparticles for doxorubicin (DOX) delivery against DOX-resistant HuCC-T1 human cholangiocarcinoma (CCA) cells. For this purpose, L-histidine methyl ester (HIS) was attached to chitosan oligosaccharide (COS) via dithiodipropionic acid (abbreviated as ChitoHISss). DOX-incorporated nanoparticles of ChitoHISss conjugates were fabricated by a dialysis procedure. DOX-resistant HuCC-T1 cells were prepared by repetitive exposure of HuCC-T1 cells to DOX. ChitoHISss nanoparticles showed spherical morphology with a small diameter of less than 200 nm. The acid pH and glutathione (GSH) addition induced changes in the size distribution pattern of ChitoHISss nanoparticles from a narrow/monomodal distribution pattern to a wide/multimodal pattern and increased the fluorescence intensity of the nanoparticle solution. These results indicate that a physicochemical transition of nanoparticles can occur in an acidic pH or redox state. The more acidic the pH or the higher the GSH concentration the higher the drug release rate was, indicating that an acidic environment or higher redox states accelerated drug release from ChitoHISss nanoparticles. Whereas free DOX showed decreased anticancer activity at DOX-resistant HuCC-T1 cells, DOX-incorporated ChitoHISss nanoparticles showed dose-dependent anticancer activity. Intracellular delivery of DOX-incorporated ChitoHISss nanoparticles was relatively increased at an acidic pH and in the presence of GSH, indicating that DOX-incorporated ChitoHISss nanoparticles have superior acidic pH- and redox-sensitive behavior. In an in vivo tumor xenograft model, DOX-incorporated ChitoHISss nanoparticles were specifically delivered to tumor tissues and then efficiently inhibited tumor growth. We suggest that ChitoHISss nanoparticles are a promising candidate for treatment of CCA.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

pH and Redox-Dual Sensitive Chitosan Nanoparticles Having Methyl Ester and Disulfide Linkages for Drug Targeting against Cholangiocarcinoma Cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…At the same time, PEGylated AuNPs provide stability and targeting to liposomes, facilitating their accumulation in the tumor. This integrated approach aims to maximize the effectiveness of cancer treatment while minimizing the side effects associated with conventional chemotherapy, thus significantly contributing to the advancement of antitumor therapy [58].…”

Section: Functionalization Of Liposomesmentioning

confidence: 99%

Revolutionizing Therapy: Nanomaterials in Liposomes Redefine the Future of Medicinal Drugs

M. Oliveira,

M.F. Duarte,

de L. Lins

et al. 2024

Liposomes - A Modern Approach in Research [Working Title]

View full text Add to dashboard Cite

Liposomes are microscopic lipid-based vesicles that have emerged as a promising vehicle for transporting therapeutic agents with precision and efficiency. From enhanced drug bioavailability to targeted delivery, combining nanomaterials and liposomes offers a transformative approach to therapeutic interventions. Encapsulating nanomaterials with drugs in liposomes holds immense significance as it enhances precision, efficiency, and targeted delivery, revolutionizing therapeutic interventions in medicine. This chapter delves into the unique properties of nanomaterials encapsulated within liposomes, examining their potential to revolutionize medicine. In addition, it highlights key advancements, challenges, and prospects in this dynamic and rapidly evolving field, providing readers with a comprehensive understanding of the revolutionary impact on the future of medicinal drugs.

show abstract

“…In the case of PEGylated therapeutics, 25–42% anti-PEG antibodies have been reported in healthy blood donors which may trigger immunogenic responses. − It is reported that PEG conjugation increases the hydrophilicity and functional response against the biological barrier which also protect nanocarriers from serum protein adsorption. , Functionalization of liposomes with PEG has been reported with reduced adsorption of protein opsonins on liposomal surfaces and improved clearance of the liposomal system from phagocytic cells in the liver and spleen during blood circulation. ,, Various PEGylated and non-PEGylated liposomes have received clinical relevance and approval . For example, Doxil (doxorubicin loaded PEGylated liposomes) is one such approved for breast and ovarian cancer. , PEGylation improves overall circulation, specific bio distribution, biocompatibility, therapeutics efficacy and response, and better tumor retention ability of liposomal hybrid nanotheranostics. , However, the immunogenicity concern associated with PEGylated liposomes, particularly the accelerated blood clearance (ABC) phenomenon, is an important consideration in developing and clinical applications of PEGylated liposomal formulations . ABC is characterized by a rapid clearance of subsequent doses of PEGylated liposomes from the bloodstream upon repeated administration, leading to decreased therapeutic efficacy .…”

Section: Liposomesmentioning

confidence: 99%

Engineered Liposomes in Interventional Theranostics of Solid Tumors

Kommineni

Chaudhari

Conde

et al. 2023

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Engineered liposomal nanoparticles have unique characteristics as cargo carriers in cancer care and therapeutics. Liposomal theranostics have shown significant progress in preclinical and clinical cancer models in the past few years. Liposomal hybrid systems have not only been approved by the FDA but have also reached the market level. Nanosized liposomes are clinically proven systems for delivering multiple therapeutic as well as imaging agents to the target sites in (i) cancer theranostics of solid tumors, (ii) image-guided therapeutics, and (iii) combination therapeutic applications. The choice of diagnostics and therapeutics can intervene in the theranostics property of the engineered system. However, integrating imaging and therapeutics probes within lipid self-assembly “liposome” may compromise their overall theranostics performance. On the other hand, liposomal systems suffer from their fragile nature, site-selective tumor targeting, specific biodistribution and premature leakage of loaded cargo molecules before reaching the target site. Various engineering approaches, viz., grafting, conjugation, encapsulations, etc., have been investigated to overcome the aforementioned issues. It has been studied that surface-engineered liposomes demonstrate better tumor selectivity and improved therapeutic activity and retention in cells/or solid tumors. It should be noted that several other parameters like reproducibility, stability, smooth circulation, toxicity of vital organs, patient compliance, etc. must be addressed before using liposomal theranostics agents in solid tumors or clinical models. Herein, we have reviewed the importance and challenges of liposomal medicines in targeted cancer theranostics with their preclinical and clinical progress and a translational overview.

show abstract

pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin

Cited by 18 publications

References 59 publications

pH and Redox-Dual Sensitive Chitosan Nanoparticles Having Methyl Ester and Disulfide Linkages for Drug Targeting against Cholangiocarcinoma Cells

pH and Redox-Dual Sensitive Chitosan Nanoparticles Having Methyl Ester and Disulfide Linkages for Drug Targeting against Cholangiocarcinoma Cells

Revolutionizing Therapy: Nanomaterials in Liposomes Redefine the Future of Medicinal Drugs

Engineered Liposomes in Interventional Theranostics of Solid Tumors

Contact Info

Product

Resources

About